Accessibility Menu
Purple Biotech logo

Purple Biotech(NASDAQ) PPBT

Market Cap$2.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year-92%
1 Month+19%
$2.15
+29.52%
+0.49Today
Purple Biotech last closing stock price
MetricPriceDate
Last closeUSD 1.662026-09-01
Purple Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.61%USD 1.652026-08-25
1 month+18.57%USD 1.402026-07-31
3 month-43.73%USD 2.952026-06-03
Year to date-74.75%USD 6.582025-12-31
1 year-91.66%USD 19.902025-08-29
3 year-99.36%USD 260.002023-09-01
5 year-99.83%USD 996.002021-09-02
Since inception-99.97%USD 5,980.002015-11-23

Purple Biotech Financials at a Glance

Market Cap

$2.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$24.49M

EPS (TTM)

-$28.06

P/E Ratio

-0.06

Dividend

$0.00

Beta (Volatility)

0.52 (Low)

Price

$2.15

Volume

62,277,793.452

Open

$2.39

Previous Close

$1.66

Daily Range

$2.11 - $2.59

52-Week Range

$1.16 - $14.89

Estimated Earnings Date

Nov 13, 2026

PPBT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Purple Biotech

Purple Biotech Ltd. is a clinical-stage biotechnology firm based in Rehovot, Israel, focused on developing innovative treatments for cancer patients. The company aims to address tumor immune evasion and drug resistance through its advanced oncology pipeline.

Products and Services
  • CM24: Monoclonal antibody targeting CEACAM1, in Phase 1b/2 trials
  • NT219: Small molecule compound targeting IRS1/2 and STAT pathways, in Phase 1/2 studies
  • Combination therapies with anti-PD-1 checkpoint inhibitors for various cancers
Growth Outlook
  • Strong pipeline with two promising oncology assets in clinical trials
  • Potential market expansion in the U.S. for cancer therapies
  • Focus on overcoming drug resistance may attract strategic partnerships
Financial Highlights
  • Recent quarterly net income of $441,000, showing positive momentum
  • Cash and short-term investments of $6.1 million as of June 30, 2026
  • Current ratio of 3.72 indicates strong liquidity position
Purple Biotech Ltd. is positioned in the biotechnology sector, specifically targeting oncology treatments. The company’s lead candidates, CM24 and NT219, are designed to tackle significant challenges in cancer therapy, such as immune evasion and drug resistance. The ongoing clinical trials for these assets are critical milestones that could enhance the company's market presence and attract potential partnerships or collaborations. Financially, the company has demonstrated a recent net income, indicating a shift towards profitability. The liquidity position, highlighted by a current ratio of 3.72, suggests that Purple Biotech is well-equipped to manage its short-term obligations. With a solid cash reserve, the company is poised to continue its research and development efforts, which are essential for long-term growth and sustainability in the competitive biotechnology landscape.
AI Generated • Aug 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10

CEO

Gil Efron, MBA, CPA

Website

www.purple-biotech.com

Headquarters

Rehovot, TA 7670104, IL

PPBT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-151.75%

Return on Capital

-275.74%

Return on Assets

-172.94%

Earnings Yield

-16.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.62M

Volume

62.28M

Avg. Volume

222.91K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$28.36M

EBITDA

-$24.28M

Operating Cash Flow

-$7.76M

Capital Expenditure

$0.00

Free Cash Flow

-$7.76M

Cash & ST Invst.

$6.11M

Total Debt

$134.00K

Purple Biotech Performance Analysis

Purple Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Purple Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Purple Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -233.5613.0%
20232023-12-31USD -161.08-31.0%
20242024-12-31USD -28.13-82.5%
20252025-12-31USD -55.4096.9%
Purple Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3030.0%
Q42025-12-31-607.1%
Q12026-03-31100.0%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$2.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$269.08K

N/A

Employees

10

N/A

Net Income

$441.00K

+140.6%

EBITDA

$520.00K

+149.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$6.11M

+3.1%

Total Debt

$134.00K

+30.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$134.00K

+30.1%

Return on Assets

-1.73%

N/A

Return on Invested Capital

-2.47%

N/A

Free Cash Flow

-$2.51M

-62.1%

Operating Cash Flow

-$2.50M

-62.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
REVBRevelation Biosciences, Inc.
$1.00+1.10%
FOXOFOXO Technologies Inc.
$0.14-6.69%
DRMADermata Therapeutics, Inc.
$1.28-1.74%
CDTCDT Equity Inc.
$1.09-26.35%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$12.89-0.08%
NVDANvidia
$223.94+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.31-0.00%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$106.88+0.01%

Questions About PPBT

What is the current price of Purple Biotech?

Purple Biotech is trading at $2.20 per share.

What is the 52-week range for Purple Biotech?

Over the past 52 weeks, Purple Biotech has traded between $1.16 and $14.89.

How much debt does Purple Biotech have?

As of the most recent reporting period, Purple Biotech reported total debt of $134.00K.

How much cash does Purple Biotech have on hand?

Purple Biotech reported $5.24M in cash and cash equivalents in its most recent financial results.

What is Purple Biotech’s dividend yield?

Purple Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services